Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Editorial: Women in radionucli...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Editorial: Women in radionuclide therapy: 2023

Editorial: Women in radionuclide therapy: 2023

Bibliographic Details
Main Authors: Egesta Lopci, Federica Matteucci
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-05-01
Series:Frontiers in Nuclear Medicine
Subjects:
radionuclide therapy
women
PRRT (peptide receptor radionuclide therapy)
radioablative iodine therapy
theranostic application
Online Access:https://www.frontiersin.org/articles/10.3389/fnume.2024.1411878/full
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://www.frontiersin.org/articles/10.3389/fnume.2024.1411878/full

Similar Items

  • Peptide receptor radionuclide therapy for ectopic Cushing’s syndrome caused by metastatic neuroendocrine neoplasms
    by: Emma Boehm, et al.
    Published: (2024-11-01)
  • Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience
    by: G Giuffrida, et al.
    Published: (2019-05-01)
  • Combination Therapy, a Promising Approach to Enhance the Efficacy of Radionuclide and Targeted Radionuclide Therapy of Prostate and Breast Cancer
    by: Tyrillshall S. T. Damiana, et al.
    Published: (2021-05-01)
  • Impressive Response to TANDEM Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu/<sup>225</sup>AcDOTA-LM3 Somatostatin Receptor Antagonist in a Patient with Therapy-Refractory, Rapidly Progressive Neuroendocrine Neoplasm of the Pancreas
    by: Elisabetta Perrone, et al.
    Published: (2024-04-01)
  • Response to targeted radionuclide therapy with [131I]MIBG AND [177Lu]Lu-DOTA-TATE according to adrenal vs. extra-adrenal primary location in metastatic paragangliomas and pheochromocytomas: A systematic review
    by: Stefan Prado-Wohlwend, et al.
    Published: (2022-10-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs